Blog

Claimed pharmacokinetics of chewable tablet were inherent result of practicing the prior art.

Trial court applied wrong legal framework to claimed new compound formed during lyophilization.

Board gives pointers on how to overcome obviousness rejection over broad prior art disclosure.

Court finds Meda Pharmaceuticals’ delay asserting certificate of correction precludes adding the corrected claim to the lawsuit.

Horizon’s formulation patent for Pennsaid® survives validity challenge and prevents generic entry in spite of narrow breadth.

Mylan's patent on the purity of isosulfan blue, a drug used by oncologists to map lymphatic drainage, was affirmed by the Federal Circuit earlier this month.

Arguments that CHO host cells were considered unsuitable for commercial scale manufacturing unavailing because commercial scale was not a limitation in the claims.

Despite carve-out of patented indication, claims of induced patent infringement proceed to trial based on skinny label.

Mechanism of Action Claims Rejected based on Definition of "Therapeutically Effective Amount"

"Consisting of" strictly construed in pharmaceutical formulation claim.